Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Autoimmune PA Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 4649-D

    Medicare Part B Step Therapy Autoimmune Conditions

    Customize your policy alerts

    Sign up for zing_health Policy 4649-D alerts

    Get alerted when Policy 4649-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of specified Medicare Part B autoimmune-condition drug products for Zing Health members. Preferred products are generally used first, while non-preferred products require prior authorization based on prior treatment, clinical intolerance or inadequate response, or other specified clinical exceptions.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Autoimmune Conditions
    Policy CodePolicy 4649-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization for non-preferred products and document prior use within 365 days or the applicable clinical exception.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Preferred autoimmune drug products
    4Non-preferred autoimmune drug products
    365 daysPrior-use lookback
    6Reasons to avoid TNF inhibitors

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    Potential preferred-product bypasses

    Non-Preferred Product Coverage Criteria

    Cimzia lyophilized powder

    Coverage for Cimzia lyophilized powder is provided when ANY of the following criteria is met.

    Cimzia lyophilized powder exception criteria

    • Prior use: Member has received treatment with Cimzia lyophilized powder in the past 365 days.past 365 days
    • Preferred-product failure or intolerance: Member has a documented inadequate response or intolerable adverse event with all preferred products whose indications overlap: Entyvio IV, Ilumya, Simponi Aria, and Tremfya IV.All applicable overlapping preferred products

      A documented primary non-responder to an IL-23 inhibitor does not need to use the corresponding preferred product from that class.

    • Pregnancy-related exception: Member is currently breastfeeding, pregnant, or planning pregnancy.

    All other non-preferred products

    Coverage for all other non-preferred products is provided when EITHER of the following criteria is met.

    Other non-preferred product exception criteria

    • Prior use: Member has received treatment with the requested non-preferred product in the past 365 days.past 365 days
    • Preferred-product failure or intolerance: Member has a documented inadequate response or intolerable adverse event with all preferred products whose indications overlap: Entyvio IV, Ilumya, Simponi Aria, and Tremfya IV.All applicable overlapping preferred products

      This criterion is subject to the documented clinical-reason exception for avoiding TNF inhibitors described in the appendix.

    TNF-inhibitor avoidance exceptions

    A clinical reason to avoid TNF inhibitors may support an exception to the applicable TNF-inhibitor step.

    Clinical reasons to avoid TNF inhibitors

    • Demyelinating disorder: History of demyelinating disorder.
    • Congestive heart failure: History of congestive heart failure.
    • Hepatitis B: History of hepatitis B virus infection.
    • Autoantibody or lupus-like syndrome: Autoantibody formation or lupus-like syndrome.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization for Non-Preferred Products

    Submit a prior authorization request for a non-preferred product when the member has a qualifying clinical exception or documented prior use. Coverage review applies to all members requesting a non-preferred product and is in addition to applicable NCD, LCD, and Medicare Part B utilization management programs.

    • Non-preferred products: Actemra IV, Cimzia lyophilized powder, Orencia IV, and Stelara IV.
    • Preferred products: Entyvio IV, Ilumya, Simponi Aria, and Tremfya IV.
    • Document the member’s indication and the clinical circumstance supporting the exception.
    Step Therapy

    Preferred Product First

    Use the preferred product pathway first for FDA-approved indications covered by this program. A non-preferred product generally requires documentation that the applicable preferred products were tried and produced an inadequate response or intolerable adverse event, unless a specified exception applies.

    Policy Background

    This policy applies to Medicare Part B autoimmune-condition drug products administered through the medical benefit. It identifies preferred and non-preferred products for applicable FDA-approved indications and establishes a preferred-product-first framework for step therapy. Preferred products may still require clinical prior authorization review, and step therapy applies in addition to applicable National Coverage Determinations, Local Coverage Determinations, and Medicare Part B utilization-management programs.

    Non-preferred products require an exception review through prior authorization. Coverage may be supported by prior use of the requested product within the past 365 days or by documented clinical circumstances, such as inadequate response, intolerable adverse events, pregnancy-related circumstances, or a clinical reason to avoid TNF inhibitors.

    Policy Definitions

    Definition
    TermIV
    MeaningIntravenous administration.
    Policy useIV identifies products administered intravenously, including Entyvio, Simponi Aria, and Tremfya.
    Definition
    TermFDA-approved indication
    MeaningA use of a drug for an indication approved by the U.S. Food and Drug Administration for the preferred product.
    Step-therapy applicationThe program applies when a member requests treatment for an indication that is FDA-approved for the preferred products.

    Initial Exception Criteria

    Cimzia lyophilized powder initial exception

    Cimzia lyophilized powder is covered when ANY of the following initial exception criteria is met.

    Cimzia initial exception criteria

    • Prior use: Member has received treatment with Cimzia lyophilized powder in the past 365 days.past 365 days
    • Preferred-product failure or intolerance: Member has a documented inadequate response or intolerable adverse event with all preferred products whose indications overlap: Entyvio IV, Ilumya, Simponi Aria, and Tremfya IV.All applicable overlapping preferred products

      A documented primary non-responder to an IL-23 inhibitor does not need to use the corresponding preferred product from that class.

    Preferred and Non-Preferred Product Sequence

    StepPreferred productsNon-preferred productsRequirement / exception
    1Entyvio IV; Ilumya; Simponi Aria; Tremfya IVActemra IV; Cimzia lyophilized powder; Orencia IV; Stelara IVUse preferred products before non-preferred products for applicable FDA-approved indications. An exception may be supported by prior use of the requested non-preferred product within the past 365 days, documented inadequate response or intolerable adverse event with applicable preferred products, pregnancy-related circumstances for Cimzia, or a documented clinical reason to avoid TNF inhibitors.
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Autoimmune Conditions
    Policy CodePolicy 4649-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization for non-preferred products and document prior use within 365 days or the applicable clinical exception.
    SourceLink
    On This Page
    Non-Preferred Product Coverage CriteriaAuthorization and Documentation RequirementsPolicy BackgroundPolicy DefinitionsInitial Exception CriteriaPreferred and Non-Preferred Product Sequence
    Malignancy concern: History or risk of lymphoma or other malignancy.
  1. TNF primary non-response: History of being a primary non-responder to a TNF inhibitor.
  2. Preferred products: Entyvio IV (vedolizumab), Ilumya (tildrakizumab-asmn), Simponi Aria (golimumab), and Tremfya IV (guselkumab).
  3. Preferred products may still require a clinical prior authorization review.
  4. Apply the preferred-product requirement only where the products’ indications overlap with the requested treatment.
  5. Documentation Required

    Document Prior Treatment or Clinical Exception

    Provide records supporting either prior treatment with the requested non-preferred product or a qualifying clinical exception. Documentation should identify the product, treatment history, indication, response, adverse event or intolerance, and the applicable preferred products with overlapping indications.

    • Document treatment with the requested non-preferred product within the past 365 days, when applicable.
    • Document inadequate response or intolerable adverse events with all applicable preferred products.
    • For Cimzia, a documented primary non-response to an IL-23 inhibitor removes the need to use the corresponding preferred product from that class.
    Documentation Required

    Cimzia-Specific Exception Documentation

    For Cimzia lyophilized powder, document the applicable pregnancy-related circumstance or a qualifying IL-23 inhibitor exception. These circumstances may support coverage without completion of the corresponding preferred-product step when the criteria are met.

    • Member is currently pregnant.
    • Member is currently breastfeeding.
    • Member is planning pregnancy.
    • Member is a documented primary non-responder to an IL-23 inhibitor.
    Documentation Required

    Document Reason to Avoid TNF Inhibitors

    For non-preferred products other than Cimzia, document the clinical reason to avoid tumor necrosis factor (TNF) inhibitors when relying on that exception. The record should identify the relevant history or risk and explain its relationship to TNF-inhibitor avoidance.

    • History of demyelinating disorder.
    • History of congestive heart failure.
    • History of hepatitis B virus infection.
    • Autoantibody formation or lupus-like syndrome.
    • History or risk of lymphoma or other malignancy.
    • History of being a primary non-responder to a TNF inhibitor.
    Denial Risk

    Non-Preferred Exception Criteria Not Established

    A non-preferred product may be denied when neither the 365-day prior-use pathway nor a qualifying clinical exception is established. Ensure the submitted records clearly support the applicable pathway before requesting authorization.

    • Document prior treatment with the requested product within the past 365 days; or
    • Document the required inadequate response, intolerable adverse event, pregnancy-related circumstance, IL-23 inhibitor non-response, or TNF-inhibitor avoidance reason, as applicable.
    • For all other non-preferred products, the TNF-inhibitor exception must include a documented clinical reason to avoid TNF inhibitors.
    Denial Risk

    Preferred-Product Step Not Completed

    A request may be denied when the required preferred-product step is incomplete and no qualifying exception is documented. Records must show inadequate response or intolerable adverse events with all preferred products whose indications overlap, unless an applicable exception removes the corresponding step.

    • Document use and outcome for Entyvio IV, Ilumya, Simponi Aria, and Tremfya IV when their indications overlap.
    • For Cimzia, a documented primary non-response to an IL-23 inhibitor may remove the corresponding preferred-product requirement.
    • For other non-preferred products, a documented clinical reason to avoid TNF inhibitors may qualify as an exception.
    Definition
    TermPrimary non-responder to an IL-23 inhibitor
    MeaningA member who does not respond to an interleukin-23 inhibitor as an initial treatment.
    Step-therapy effectA documented primary non-responder to an IL-23 inhibitor does not need to use the corresponding preferred product from that class.
    Pregnancy-related exception: Member is currently breastfeeding, pregnant, or planning pregnancy.

    Other non-preferred products initial exception

    All other non-preferred products are covered when EITHER initial exception criterion is met.

    Other non-preferred initial exception criteria

    • Prior use: Member has received treatment with the requested non-preferred product in the past 365 days.past 365 days
    • Preferred-product failure or intolerance: Member has a documented inadequate response or intolerable adverse event with all preferred products whose indications overlap: Entyvio IV, Ilumya, Simponi Aria, and Tremfya IV.All applicable overlapping preferred products

      A documented clinical reason to avoid TNF inhibitors may provide an exception to the applicable TNF-inhibitor step.